[go: up one dir, main page]

GB202109896D0 - Novel treatments - Google Patents

Novel treatments

Info

Publication number
GB202109896D0
GB202109896D0 GBGB2109896.7A GB202109896A GB202109896D0 GB 202109896 D0 GB202109896 D0 GB 202109896D0 GB 202109896 A GB202109896 A GB 202109896A GB 202109896 D0 GB202109896 D0 GB 202109896D0
Authority
GB
United Kingdom
Prior art keywords
novel treatments
treatments
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2109896.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides AB
Original Assignee
Oncopeptides AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides AB filed Critical Oncopeptides AB
Priority to GBGB2109896.7A priority Critical patent/GB202109896D0/en
Publication of GB202109896D0 publication Critical patent/GB202109896D0/en
Ceased legal-status Critical Current

Links

GBGB2109896.7A 2021-07-08 2021-07-08 Novel treatments Ceased GB202109896D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2109896.7A GB202109896D0 (en) 2021-07-08 2021-07-08 Novel treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2109896.7A GB202109896D0 (en) 2021-07-08 2021-07-08 Novel treatments

Publications (1)

Publication Number Publication Date
GB202109896D0 true GB202109896D0 (en) 2021-08-25

Family

ID=77353841

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2109896.7A Ceased GB202109896D0 (en) 2021-07-08 2021-07-08 Novel treatments

Country Status (1)

Country Link
GB (1) GB202109896D0 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096367A1 (en) 2000-06-13 2001-12-20 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
WO2012146625A1 (en) 2011-04-28 2012-11-01 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065741A1 (en) 2012-10-22 2014-05-01 Parker Hannifin Manufacturing Sweden Ab Joystick
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
WO2020212594A1 (en) 2019-04-17 2020-10-22 Oncopeptides Ab Novel formulations comprising melflufen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096367A1 (en) 2000-06-13 2001-12-20 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
WO2012146625A1 (en) 2011-04-28 2012-11-01 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065741A1 (en) 2012-10-22 2014-05-01 Parker Hannifin Manufacturing Sweden Ab Joystick
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
WO2020212594A1 (en) 2019-04-17 2020-10-22 Oncopeptides Ab Novel formulations comprising melflufen

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BYRN ET AL., PHARM RES, vol. 12, no. 7, 1995, pages 945 - 954
ELNAIRHOLSTEIN, ONCOLOGY, vol. 35, pages 170 - 182
MOREAU, P. ET AL., J CLIN ONCOL, vol. 29, 2011, pages 1898 - 1906
NCCN: "NCCN Guidelines for Patients", NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, Retrieved from the Internet <URL:https://www.nccn.org/patients/guidelines/content/PDF/myeloma-patient.pdf>
PALUMBO, A. ET AL., J CLIN ONCOL, vol. 32, 2014, pages 587 - 600
PIECHOTTA V ET AL.: "Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 2019, no. CD013487
RICHARDSON, P. G. ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 7, 2021, pages 757 - 767
ROSINOL, L. ET AL., EXPERT REV HEMATOL, vol. 7, 2014, pages 43 - 53
STILLER CA ET AL., CANCER EPIDEMIOL., vol. 56, 2018, pages 146 - 153
WANG, Y. J.HANSON, M. A., JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, TECHNICAL REPORT, no. 10, 1988

Similar Documents

Publication Publication Date Title
GB202006390D0 (en) Novel treatments
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202116339D0 (en) Novel treatments
GB202112977D0 (en) Novel treatments
GB202112981D0 (en) Novel treatments
GB202112980D0 (en) Novel treatments
GB202112979D0 (en) Novel treatments
GB202112978D0 (en) Novel treatments
GB202112976D0 (en) Novel treatments
GB202109895D0 (en) Novel treatments
GB202109894D0 (en) Novel treatments
GB202109896D0 (en) Novel treatments
GB202103400D0 (en) Novel treatments
GB202101291D0 (en) Novel treatments
GB202101292D0 (en) Novel treatments
GB202101296D0 (en) Novel treatments
GB202017858D0 (en) Novel treatments
GB202010259D0 (en) Novel Treatments
GB202317035D0 (en) Novel treatments
GB202316907D0 (en) Novel treatments
GB202205069D0 (en) Novel treatments
GB202205070D0 (en) Novel treatments
GB202009086D0 (en) New treatments

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)